Results 11 to 20 of about 307,259 (361)

Hypoimmune induced pluripotent stem cells survive long term in fully immunocompetent, allogeneic rhesus macaques

Nature Biotechnology, 2023
A genetic method to block immune rejection of allogeneic cells is validated in monkeys. Genetic engineering of allogeneic cell therapeutics that fully prevents rejection by a recipient’s immune system would abolish the requirement for immunosuppressive ...
Xiaomeng Hu, K. White, Ari G. Olroyd, Rowena deJesus, Antonia Dominguez, William E. Dowdle, Annabelle M. Friera, C. Young, Frank Wells, Elaine Y. Chu, C. Ito, Harini Krishnapura, Surbhi Jain, Ramya Ankala, T. Mcgill, A. Lin, Kyla Egenberger, Allison Gagnon, J. Michael Rukstalis, Nathaniel J. Hogrebe, Corie Gattis, R. Basco, J. Millman, P. Kievit, Mark M. Davis, L. Lanier, A. Connolly, T. Deuse, S. Schrepfer   +28 more
semanticscholar   +1 more source

Engraftment of allogeneic iPS cell-derived cartilage organoid in a primate model of articular cartilage defect

Nature Communications, 2023
Induced pluripotent stem cells (iPSCs) are a promising resource for allogeneic cartilage transplantation to treat articular cartilage defects that do not heal spontaneously and often progress to debilitating conditions, such as osteoarthritis.
Kengo Abe, A. Yamashita, Miho Morioka, N. Horike, Y. Takei, Saeko Koyamatsu, K. Okita, S. Matsuda, N. Tsumaki   +8 more
semanticscholar   +1 more source

Expanding applications of allogeneic platelets, platelet lysates, and platelet extracellular vesicles in cell therapy, regenerative medicine, and targeted drug delivery

Journal of Biomedical Sciences, 2023
Platelets are small anucleated blood cells primarily known for their vital hemostatic role. Allogeneic platelet concentrates (PCs) collected from healthy donors are an essential cellular product transfused by hospitals to control or prevent bleeding in ...
T. Burnouf, Ming-Li Chou, David J. Lundy, Er-Yuan Chuang, Ching-Li Tseng, H. Goubran   +5 more
semanticscholar   +1 more source

Hypoimmune anti-CD19 chimeric antigen receptor T cells provide lasting tumor control in fully immunocompetent allogeneic humanized mice

Nature Communications, 2023
The development of allogeneic chimaeric antigen receptor (CAR) T cells could overcome manufacturing bottlenecks for immunotherapy. However, immune rejection reduces the persistence and efficacy of these cells.
Xiaomeng Hu, Karl Manner, Rowena deJesus, K. White, Corie Gattis, Priscilla Ngo, C. Bandoro, E. Tham, Elaine Y. Chu, C. Young, Frank Wells, R. Basco, Annabelle M. Friera, Divy Kangeyan, Pascal R. Beauchesne, William E. Dowdle, T. Deuse, T. Fry, Aaron E. Foster, S. Schrepfer   +19 more
semanticscholar   +1 more source

Allogeneic natural killer cell therapy

Blood, 2022
Visual ...
M. Berrien-Elliott, Miriam T. Jacobs, T. Fehniger   +2 more
semanticscholar   +1 more source

Microbiota as Predictor of Mortality in Allogeneic Hematopoietic-Cell Transplantation

New England Journal of Medicine, 2020
BACKGROUND Relationships between microbiota composition and clinical outcomes after allogeneic hematopoietic-cell transplantation have been described in single-center studies.
J. Peled, Antonio L. C. Gomes, S. Devlin, E. Littmann, Y. Taur, A. Sung, D. Weber, D. Hashimoto, Ann E. Slingerland, J. Slingerland, M. Maloy, Annelie G. Clurman, C. Stein-Thoeringer, K. Markey, Melissa Docampo, Marina Burgos da Silva, N. Khan, A. Gessner, J. Messina, Kristi M. Romero, M. Lew, A. Bush, L. Bohannon, Daniel G. Brereton, E. Fontana, L. Amoretti, R. Wright, G. Armijo, Y. Shono, Míriam Sanchez-Escamilla, Nerea Castillo Flores, A. Alarcon Tomas, R. Lin, Lucrecia Yáñez San Segundo, G. Shah, C. Cho, M. Scordo, I. Politikos, Kasumi Hayasaka, Y. Hasegawa, B. Gyurkocza, D. Ponce, J. Barker, M. Perales, S. Giralt, R. Jenq, T. Teshima, N. Chao, E. Holler, J. Xavier, E. Pamer, M. V. D. van den Brink   +51 more
semanticscholar   +1 more source

Allogeneic CAR Cell Therapy—More Than a Pipe Dream

Frontiers in Immunology, 2021
Adoptive cellular immunotherapy using immune cells expressing chimeric antigen receptors (CARs) has shown promise, particularly for the treatment of hematological malignancies.
Kenneth J. Caldwell, S. Gottschalk, A. Talleur   +2 more
semanticscholar   +1 more source

Successful allogeneic hematopoietic stem cell transplantation in patients with VEXAS syndrome: a 2-center experience

Blood Advances, 2021
Key Points Allogeneic hematopoietic stem cell transplantation is a curative option in patients with VEXAS syndrome and severe manifestations.
Ava Diarra, Nicolas Duployez, É. Fournier, C. Preudhomme, V. Coiteux, L. Magro, B. Quesnel, M. Heiblig, P. Sujobert, F. Barraco, M. Balsat, Quentin Scanvion, E. Hachulla, D. Launay, I. Yakoub-Agha, L. Terriou   +15 more
semanticscholar   +1 more source

Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT.

Blood, 2005
We previously reported that the Charlson Comorbidity Index (CCI) was useful for predicting outcomes in patients undergoing allogeneic hematopoietic cell transplantation (HCT). However, the sample size of patients with scores of 1 or more, captured by the
M. Sorror, M. Maris, R. Storb, F. Baron, B. Sandmaier, D. Maloney, B. Storer   +6 more
semanticscholar   +1 more source

Allogeneic cell therapy bioprocess economics and optimisation: Single-use cell expansion technologies. [PDF]

, 2014
For allogeneic cell therapies to reach their therapeutic potential, challenges related to achieving scalable and robust manufacturing processes will need to be addressed. A particular challenge is producing lot-sizes capable of meeting commercial demands
Warren, K, Sally Hassan, Ana S. Simaria, Vanek, P, Varadaraju, H, Jon Rowley, Philip Vanek, Rowley, J, Farid, SS, Kim Warren, Hassan, S, Hemanthram Varadaraju, Simaria, AS, Suzanne S. Farid   +13 more
core   +1 more source